RCS - Creo Medical Group - Royal Oldham Hospital Agreement

Creo MedicalAnnouncement

17/05/2023 07:17

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230517:nRSQ6460Za&default-theme=true

RNS Number : 6460Z  Creo Medical Group PLC  17 May 2023

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

The Royal Oldham Hospital becomes first NHS hospital to immediately implement
CROMA and Speedboat™ Inject across multiple Endoscopy rooms

Multiple doctors already working through regular weekly SSD lists after
significant order

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, announces that The Royal Oldham Hospital
is the latest NHS England hospital to become a high-volume site for Speedboat
Inject, with the device supporting their goal to prevent and treat bowel
cancer.

 

Having recently completed simultaneous training of multiple doctors through
Creo's Pioneer clinical education and mentoring programme, the hospital has
quickly ordered and taken delivery of several CROMA Advanced Energy platforms,
Speedboat Inject devices and associated endotherapy products, before putting
in place   weekly lists for multiple SSD (Speedboat Submucosal Dissection)
cases and the associated routine ordering of equipment to support these
services.

 

As part of Creo's Pioneer Clinical Education Programme in late April, three
doctors at the Royal Oldham each performed their first in-hospital SSD
procedures using Speedboat Inject, with a total of five cases successfully
completed during a single afternoon. The Royal Oldham's CEO and Managing
Director of Surgery were present to witness Creo's technology and the
hospital's endoscopy team has since successfully performed over a dozen
further cases. The service has been supported by high quality mentoring from
Creo Medical, enabling new trainees to transition easily into regular users.

 

Creo Medical expects to see continued high usage by the three new physicians
as they support the Trust as it tackles NHS waiting lists cost effectively.
SSD has already provided savings of up to £10k per procedure compared to the
surgical alternative. Most importantly, this should help hundreds of patients
per year to avoid more invasive procedures and the complications that can come
with them.

 

The Royal Oldham Hospital is the twenty-third NHS England healthcare setting
to adopt SSD, with twelve now high-volume users. Creo Medical conservatively
estimates that there are over 350 hospitals in the UK whose patients could
benefit from Speedboat Inject and the associated SSD procedure.

 

Dr Sal Khalid, Consultant Gastroenterologist at the Royal Oldham Hospital
said: "I am delighted that we will be able to provide this state of the art,
safe and effective treatment for our patients at their local hospital. This is
a great step forward in the treatment we provide with the technique reducing
the chances of recurrence following the removal of a lesion from 15 percent to
1 percent.

 

"This procedure will help us with our goal towards prevention, early detection
and treatment of bowel cancer."

 

Dr Regi George, Gastroenterologist at The Royal Oldham Hospital added: "I have
been doing advanced procedures over many years and have used most of the
current monopolar knives available in the market both in the upper and lower
GI tract.

 

"However, the Speedboat device is a game changer. This is a safer technology
and allows much deeper submucosal dissection. We are now moving on to use this
as our preferred and only device for endoscopic dissection."

 

 

Craig Gulliford, Creo Medical CEO said: "I am really pleased to see the team
at The Royal Oldham Hospital become the latest adopters of Speedboat Inject.

 

"Our business strategy, focussed on training and mentoring, has been very
clear and honed in particular after the COVID pandemic.  For a hospital such
as Oldham to be enrolling multiple doctors into our Pioneer Education program
simultaneously and then immediately cementing this commitment with weekly
patient lists across multiple endoscopy rooms backed up with product ordering
in place is a great demonstration of the progress that we are making. It also
reinforces what we are beginning to also see elsewhere - that the
establishment of multiple services with our advanced energy platform and
single use devices helps accelerate the scale at which patients benefit from
the technology, alongside the associated business this creates for Creo
Medical."

 

Luis Collantes, European President of Creo, added: "This latest contract
further demonstrates the excellent progress hospitals such as Royal Oldham are
making in understanding and implementing the advantages of our advanced energy
technology, ensuring the benefits to patients and hospitals are maximised with
the best service possible by offering high quality endoscopy solutions. It's
exciting to see Creo Medical become a complete solution for excellent services
like this one at Royal Oldham."

 

 

Enquiries:

 

 Creo Medical Group plc                            www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                +44 (0)1291 606 005

 Cenkos Securities plc                             +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Joint Broker)

 Numis Securities Limited (Joint Broker)           +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                   Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 / Phillip Marriage

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAAFMMTMTTBTTJ